The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis

Toohey, Kellie; Chapman, Michael; Rushby, Anne-Marie; Urban, Kat; Ingham, Gemma; Singh, Benjamin

doi:10.1007/s11764-021-01153-0

Cited by 38 publications

(35 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few human studies have examined exercise in patients with treatment naïve metastatic disease. Generally speaking, exercise studies in patients with metastatic disease have not distinguished among patients who were treatment naïve, actively treated, or previously treated (37). Moreover, most human exercise research in these clinical settings has used case studies, qualitative studies, surveys, and feasibility designs, however, few have reported on cancer outcomes (37).…”

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

“…Generally speaking, exercise studies in patients with metastatic disease have not distinguished among patients who were treatment naïve, actively treated, or previously treated (37). Moreover, most human exercise research in these clinical settings has used case studies, qualitative studies, surveys, and feasibility designs, however, few have reported on cancer outcomes (37). The focus has been on palliative outcomes and the research has shown that exercise is feasible for some patients and may provide modest benefits (37).…”

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

“…Moreover, most human exercise research in these clinical settings has used case studies, qualitative studies, surveys, and feasibility designs, however, few have reported on cancer outcomes (37). The focus has been on palliative outcomes and the research has shown that exercise is feasible for some patients and may provide modest benefits (37).…”

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

“…Limited human studies have examined the effects of exercise during treatment for metastatic disease, although some have reported cancer outcomes (37,39). In a systematic review and meta-analysis of 11 studies of exercise and survival outcomes in patients with advanced cancer, exercise was associated with improved survival in 7 observational studies but not in 4 randomized controlled trials (39).…”

Section: Scenario #8: Actively Treated Metastatic Diseasementioning

confidence: 99%

“…To date, there are very few preclinical exercise studies focused on exercise as a cancer treatment in this clinical scenario. To examine the effects of exercise on previously treated metastatic disease in animal models, the most clinically relevant model would be to establish a primary tumor, allow it to As noted earlier, human exercise studies in patients with metastatic disease have typically included patients with mixed treatment status and focused on feasibility and palliative outcomes (37). Study designs have consisted of case studies, qualitative studies, surveys, and feasibility studies designs.…”

Section: Scenario #9:previously Treated Metastatic Diseasementioning

confidence: 99%

See 4 more Smart Citations

Exercise as cancer treatment: A clinical oncology framework for exercise oncology research

Courneya

Booth

2022

Front. Oncol.

View full text Add to dashboard Cite

Exercise has been proposed as a possible cancer treatment; however, there are an infinite number of clinical oncology settings involving diverse cancer types and treatment protocols in which exercise could be tested as a cancer treatment. The primary purpose of this paper is to propose a conceptual framework to organize and guide research on exercise as a cancer treatment across distinct clinical oncology settings. A secondary purpose is to provide an overview of existing exercise research using the proposed framework. The Exercise as Cancer Treatment (EXACT) framework proposes nine distinct clinical oncology scenarios based on tumor/disease status and treatment status at the time of the proposed exercise treatment. In terms of tumor/disease status, the primary tumor has either been surgically removed (primary goal to treat micrometastases), not surgically removed (primary goal to treat the primary tumor), or metastatic disease is present (primary goal to treat metastatic disease). In terms of treatment status, the extant disease has either not been treated yet (treatment naïve), is currently being treated (active treatment), or has previously been treated. These two key clinical oncology variables—tumor/disease status and treatment status—result in nine distinct clinical oncology scenarios in which exercise could be tested as a new cancer treatment: (a) treatment naïve micrometastases, (b) actively treated micrometastases, (c) previously treated micrometastases, (d) treatment naïve primary tumors, (e) actively treated primary tumors, (f) previously treated primary tumors, (g) treatment naïve metastatic disease, (h) actively treated metastatic disease, and (i) previously treated metastatic disease. To date, most preclinical animal studies have examined the effects of exercise on treatment naïve and actively treated primary tumors. Conversely, most observational human studies have examined the associations between exercise and cancer recurrence/survival in patients actively treated or previously treated for micrometastases. Few clinical trials have been conducted in any of these scenarios. For exercise to be integrated into clinical oncology practice as a cancer treatment, it will need to demonstrate benefit in a specific clinical setting. The EXACT framework provides a simple taxonomy for systematically evaluating exercise as a potential cancer treatment across a diverse range of cancer types and treatment protocols.

show abstract

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

Section: Scenario #7: Treatment Naïve Metastatic Diseasementioning

confidence: 99%

Section: Scenario #8: Actively Treated Metastatic Diseasementioning

confidence: 99%

Section: Scenario #9:previously Treated Metastatic Diseasementioning

confidence: 99%

See 3 more Smart Citations

Exercise as cancer treatment: A clinical oncology framework for exercise oncology research

Courneya

Booth

2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

The Potential of Wearable Devices in Cancer Care Delivery

Hawley,

Haymart

2024

JAMA Oncol

View full text Add to dashboard Cite

Wearable devices, or devices worn on the bodies of patients such as the Apple Watch, FitBit, or other monitoring devices, offer opportunities to innovate and improve cancer care delivery, from prevention and screening through survivorship.Fueled partly by the COVID-19 pandemic and growing need for remote and virtual care, the number of studies of technology-supported health interventions in cancer-including studies on wearables in cancer care-has increased dramatically in the past 3 to 5 years. 1,2 These studies underscore the potential offered by wearable devices across the landscape of cancer care delivery. Wearable devices may be used to support a range of activities including real-time monitoring of patient data, such as heart rate, blood pressure, or sleep quality, as well as allowing patients to directly report symptoms and mood using the wearable device. This allows for more accurate and ongoing healthrelated data collection for patients that can be used to manage and adjust treatment and to predict the potential for negative outcomes such as hospitalization. Integrating wearable devices into cancer care delivery holds promise for improving outcomes for patients across the care continuum.This issue of JAMA Oncology includes 2 studies that evaluated the use of wearable devices in different contexts. 3,4 Ito et al 3 assessed use of a wearable device (specifically the amuelink [Sony], which is worn around one's waist for the entire day) to measure physical activity in 119 patients with nonsmall cell lung cancer as an alternative to the traditionally used and patient-reported Eastern Cooperative Oncology Group Performance Scale (ECOG PS) to assess outcomes, including survival. They found that mean distanced walked obtained from the wearable was the best possible predictor of 6-month survival. The authors concluded that wearables, such as the one studied, provide more objective data than the subjectively assessed ECOG PS.Friesner et al 4 used data from 3 prospective trials in which a total of 214 patients with a variety of solid tumors (primary sites including the lung and head/neck) used wearable devices during chemoradiation. The authors' objective was to develop and validate a machine learning approach to predict unplanned hospitalizations associated with chemoradiation toxic effects based on daily step count from the wearable devices. The elastic net-regularized logistic regression (EN) with step count performed similarly to the EN with step count and clinical features. The authors concluded that EN models with step count plus clinical features or step count alone have potential to predict hospitalization during chemoradiation. The models developed from this work are being implemented in a larger study within NRG Oncology. 5 Opinion EDITORIAL jamaoncology.com (Reprinted)

show abstract

The content and effectiveness of physical activity for cancer‐related fatigue among colorectal cancer survivors: Systematic review and meta‐analysis

Geng

Guo

et al. 2023

Nursing Open

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most frequent cancer globally; according to the latest data, the incidence of new colorectal cancer cases was as high as 10%, and the number of new cases worldwide reached 1.93 million in 2020 (Sung et al., 2021). One of the most common treatment options for CRC in clinical practice is radical resection combined with chemotherapy, which has greatly improved the survival rate (Iveson et al., 2019). However, the quality of life of CRC patients has not been promoted significantly due to the many adverse effects caused by cancer itself and treatments, especially chemotherapy, such as chronic pain, sleep disturbances, fatigue, depression and so on (Ketelaers et al., 2022;Sakr et al., 2020).Therefore, the burden of follow-up care for CRC survivors is expected to increase, and exploring ways to improve cancer-related symptoms and quality of life in this population deserves attention.Cancer-related fatigue (CRF), a sustained and distressing sense of tiredness or exhaustion, is currently recognized as one of the

show abstract

The effects of physical exercise in the palliative care phase for people with advanced cancer: a systematic review with meta-analysis

Cited by 38 publications

References 68 publications

Exercise as cancer treatment: A clinical oncology framework for exercise oncology research

Exercise as cancer treatment: A clinical oncology framework for exercise oncology research

The Potential of Wearable Devices in Cancer Care Delivery

The content and effectiveness of physical activity for cancer‐related fatigue among colorectal cancer survivors: Systematic review and meta‐analysis

Contact Info

Product

Resources

About